Gossamer Bio, Inc. (GOSS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Gossamer Bio, Inc. (GOSS) closed at USD 8.90 on 2026-10-14, a change of -95.3 % over the past year, with a market capitalization of USD 54.37M.

Gossamer Bio, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Gossamer Bio, Inc. key figures

Previous close

USD 8.90 (2026-10-14)

1-year change

-95.3 %

Market cap

USD 54.37M

Enterprise value

USD 37.37M

P/E ratio (trailing)

-0.17

P/E ratio (forward)

-0.57

EPS (trailing)

-52.80

EPS (forward)

-15.61

PEG ratio

n/a

Price to book

-46.30

Revenue growth

-19.6 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.57

Employees

161

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Gossamer Bio, Inc.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Gossamer Bio, Inc. and compare it with other stocks.